» Articles » PMID: 27793525

Immunohistochemical Expression and Localization of Cytokines/chemokines/growth Factors in Gastric Cancer

Overview
Journal Cytokine
Date 2016 Oct 30
PMID 27793525
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Our previous studies on gastric cancer tissue and patient plasma samples identified several cytokines/chemokines/growth factors to be differentially expressed, compared to normal samples. In this study our aim was to understand the localization patterns of the markers in gastric tissues. We investigated the expression of PDGFRB, CCL3, MMP3, CXCL8, CXCL10, CCL20, IGFBP3, CXCL9, SPP1, CCL18, TIMP1, CCL15, CXCL5 and CCL4 in gastric tissues using Immunohistochemistry (IHC) on Tissue Microarrays (TMA). The TMA comprised of 25 apparently normal (AN), 87 paired normal (PN) and 134 gastric cancer (T) tissues. The epithelial and stromal expression of markers and their correlation with patient characteristics and outcome were analyzed. Several of the markers [PDGFRB (p<0.001), CCL3 (p<0.001), MMP3 (p<0.001), CXCL8 (p<0.001), CXCL10 (p<0.001), CCL20 (p<0.001), CXCL9 (p<0.001), CCL18 (p<0.001), TIMP1 (p=0.025), CCL15 (p<0.001)] were elevated in the stromal compartment of gastric cancers compared to AN tissues, with some having intermediate levels of expression in PN tissues. Epithelial and stromal PDGFRB (p=0.030, p=0.018) expression was associated with diffuse type gastric cancer. Stromal IGFBP3 (p=0.039), CXCL8 (p=0.008), TIMP1 (p<0.001), CCL4 (p=0.003) and SPP1 (p=0.048) expression was associated with intestinal type gastric cancer. Kaplan-Meier analysis showed higher epithelial PDGFRB (p=0.005 and p=0.004), CXCL8 (p=0.009 and p=0.007) were associated with poor disease free and overall survival. In multivariate analysis, high epithelial PDGFRB (p=0.036 and p=0.02) and SPP1 (p=0.003 and p<0.001) were independent prognostic factors for DFS and OS in patients with gastric cancer. The expression of cytokine/chemokine/growth factor markers is higher in the gastric tumor stroma compared to the normal gastric stroma and PDGFRB and SPP1 may serve as potential prognostic factors in gastric cancer.

Citing Articles

High CXCL8 expression predicting poor prognosis in triple-negative breast cancer.

Tang S, Zhang Y, Song L, Hui K, Jiang X Anticancer Drugs. 2025; 36(3):246-252.

PMID: 39761194 PMC: 11781556. DOI: 10.1097/CAD.0000000000001678.


Pachymic acid promotes ferroptosis and inhibits gastric cancer progression by suppressing the PDGFRB-mediated PI3K/Akt pathway.

Nie J, Zhang H, Li X, Qin J, Zhou J, Lu Y Heliyon. 2024; 10(20):e38800.

PMID: 39512319 PMC: 11541463. DOI: 10.1016/j.heliyon.2024.e38800.


Machine learning identifies a 5-serum cytokine panel for the early detection of chronic atrophy gastritis patients.

An F, Ge Y, Ye W, Ji L, Chen K, Wang Y Cancer Biomark. 2024; 41(1):25-40.

PMID: 39269824 PMC: 11495322. DOI: 10.3233/CBM-240023.


Quantifying spatial CXCL9 distribution with image analysis predicts improved prognosis of triple-negative breast cancer.

Cao X, Song Y, Wu H, Ren X, Sun Q, Liang Z Front Genet. 2024; 15:1421573.

PMID: 38957805 PMC: 11217326. DOI: 10.3389/fgene.2024.1421573.


LncRNA TRPM2-AS promotes endometrial carcinoma progression and angiogenesis via targeting miR-497-5p/SPP1 axis.

Ma H, Weng F, Tong X, Li H, Yao Y, Yuan J Cell Mol Biol Lett. 2024; 29(1):93.

PMID: 38956502 PMC: 11218065. DOI: 10.1186/s11658-024-00612-7.